News

Molecular Partners Reports Financial Results And Highlights From Q1 2025
Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected ...
Long sterol synthesis pathways help cells balance lipids and form membrane domains
Sterols, such as cholesterol in our bodies or ergosterol in yeast cells, are among the most abundant lipids in eukaryotic ...
Precigen Reports First Quarter 2025 Financial Results And Business Updates
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP <li /> Company's BLA for PRGN-2012 for the treatment of ...
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...